Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01891708
NCT01891708UnknownNot Applicable

VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

Li Liu1 site in 1 country40 target enrollmentStarted: June 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
PFS
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer

Detailed Description

  1. non small cell lung cancer (non squamous carcinoma)
  2. ECOG 0-1
  3. from 18-75 years old

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •non squamous cell non small cell lung cancer
  • •with measurable disease

Exclusion Criteria

  • •patients received surgery in recent 4 weeks

Outcomes

Primary Outcomes

PFS

Time Frame: 6 months

Secondary Outcomes

  • OS(18 months)

Investigators

Sponsor
Li Liu
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Li Liu

Professor

Huazhong University of Science and Technology

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
Radiolabeled bevacizumab as a tracer of VEGF expression in patients with colorectal liver metastasescolorectal liver metastases10027476
NL-OMON29757niversitair Medisch Centrum Sint Radboud10
Completed
Not Applicable
Polymorphism Interaction to Predict Bevacizumab EfficacyMetastatic Breast Cancer
NCT01935102University of Pisa169
Withdrawn
Not Applicable
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor PatientsGliomaMeningioma
NCT00985036Marquette General Health System
Recruiting
Not Applicable
Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of RadiochemotherapyRadiotherapyChemotherapyGlioblastoma
NCT03144167Centre Hospitalier Universitaire, Amiens170
Completed
Not Applicable
The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary FunctionColorectal CancerLung CancerBreast CancerGlioblastoma
NCT00973557Cedars-Sinai Medical Center6
VEGFRs Predict Bevacizumab Benefit in... | Clinical Trial